Anjana K Yeldandi

Suggest Changes
Learn More
BACKGROUND Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been introduced in the standard therapy of non-small-cell lung cancer (NSCLC), but they benefit a minority of(More)